The STAT3 inhibitor S3I-201 suppresses fibrogenesis and angiogenesis in liver fibrosis - Wang, Zhuo; Li, Jia'an; Xiao, Wen'ang; Long, Jiafu; Zhang, Hongmin (Laboratory investigation, 2018)
Keywords: 13/1; 13/106; 13/2; 13/31; 13/51; 13/95; 14/19; 631/154/556; 64/60; 692/699/1503/1607/1605; 82/29; 82/80; 96/21; Actin; AKT protein; Aminosalicylic Acids - pharmacology; Aminosalicylic Acids - therapeutic use; Angiogenesis; Animals; Antineoplastic Agents - pharmacology; Apoptosis; Apoptosis - drug effects; Benzenesulfonates - pharmacology; Benzenesulfonates - therapeutic use; Bile; Carbon tetrachloride; Cell cycle; Cell Line; Cell proliferation; Collagen (type I); Deoxyribonucleic acid; Dimerization; DNA; Drug Synergism; Fibrosis; Hepatic Stellate Cells - drug effects; Humans; Inhibitors; Laboratory Medicine; Liver; Liver cancer; Liver Cirrhosis - prevention & control; Male; Medicine; Medicine & Public Health; Mice, Inbred BALB C; Neovascularization, Physiologic - drug effects; Organic chemistry; Pathology; Phosphorylation; Primary Cell Culture; Receptor, Transforming Growth Factor-beta Type II - metabolism; Smad2 protein; Smad3 protein; Sorafenib - pharmacology; Stat3 protein; STAT3 Transcription Factor - antagonists & inhibitors; Stellate cells; Synergistic effect; Tissue inhibitor of metalloproteinase 1; Transcription; Transforming Growth Factor beta1 - metabolism; Transforming growth factor-b1; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - metabolism